Genmab (GMAB) has released an update.
Genmab A/S, a Copenhagen-based biotechnology company, has updated its Articles of Association, including provisions for share capital and the issuance of warrants and convertible debt instruments. Share capital is set at DKK 66,136,909 with additional authorizations for the Board to increase capital through new shares and debt instruments until March 2029. The company emphasizes medical research and the production and sale of related products, with a focus on both domestic and international markets.
For further insights into GMAB stock, check out TipRanks’ Stock Analysis page.
